It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2021
  5. Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets

August 18, 2021

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets

Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval in Japan for an orally-disintegrating-dose (OD) form of REXULTI® (brexpiprazole) tablets.

REXULTI® OD 0.5 mg, 1 mg, and 2 mg tablets will now become available in addition to the already available regular tablets in 1mg and 2mg doses. REXULTI® OD Tablets are a dose form that quickly disintegrate in the oral cavity so that it is easy to take for patients who cannot take the tablet due to difficulty in swallowing.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

It received manufacturing and marketing approval in Japan for the indication of schizophrenia in 2018.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases